GMG secures EPA approval milestone for THERMAL-XR® ENHANCE as US commercialisation advances

Graphene Manufacturing Group CEO Craig Nicol joined Steve Darling from Proactive to provide an update on the company’s commercialisation progress, highlighting a major regulatory milestone for its THERMAL-XR® ENHANCE graphene coating product. GMG announced it has received and accepted the United States Environmental Protection Agency’s consent notice approval conditions under the Pre-Manufacture Notice (PMN) process, clearing an important step toward full market entry in the United States. The EPA consent notice represents a significant achievement for GMG, as the PMN program is designed to ensure the safety and environmental suitability of new chemical substances introduced into the U.S. market. With this approval milestone in place, THERMAL-XR® ENHANCE is positioned to offer meaningful energy savings and enhanced corrosion resistance for U.S. consumers and commercial users across a range of industrial and building applications. Nicol explained that, upon receipt of the fully signed consent notice from the EPA—expected early in the new year—the first commercial shipment of THERMAL-XR® ENHANCE will be sent to Nu-Calgon. The product will be distributed and resold under the name “Nu-Calgon CoolWorx® powered by GMG Graphene,” marking GMG’s initial commercial rollout of the technology in the U.S. market. Beyond coatings, Nicol also provided an update on GMG’s Graphene Aluminium-Ion (G+AI) Battery technology, which is being developed in collaboration with the University of Queensland under a Joint Development Agreement with Rio Tinto, one of the world’s largest mining and metals companies. The project is also supported by the Battery Innovation Center of Indiana in the United States, strengthening the development and validation framework for the technology. GMG reported that, at its current stage of development, the G+AI Battery demonstrates performance characteristics comparable to high-power Lithium Titanate Oxide (LTO) batteries, which typically sell at premium prices of up to US$1,500 per kilowatt-hour. Importantly, GMG believes its graphene-based battery can be manufactured at a substantially lower cost, enabling pricing below that of LTO batteries. In 2025, global sales of LTO batteries reached approximately US$5.6 billion, underscoring the scale of the addressable market. Looking ahead, GMG management believes continued optimization of the cathode, anode, electrolyte, and overall component weight could enable the G+AI Battery to achieve energy densities of more than 150 Wh/kg when charged in one hour, and over 75 Wh/kg with ultra-fast six-minute charging. The company sees these performance targets as key drivers for future commercial competitiveness across a wide range of global energy storage applications. #GrapheneManufacturingGroup #CraigNicol #THERMALXR #GLubricant #REACHapproval #HVACR #CleanTech #GrapheneTechnology #EnergyEfficiency #SustainableTech #NuCalgon #SprayAcademy #EPAapproval #EuropeanMarket #ProactiveInvestors

Medicus Pharma Chief Medical Officer Dr. Faisel Mehmud joined Steve Darling from Proactive to announce that the company has entered into a non-binding letter of intent with Reliant AI, a decision-intelligence company specializing in generative artificial intelligence for the life sciences. The proposed collaboration is focused on developing an AI-powered data analytics platform designed to enhance clinical trial execution through advanced, data-driven insights. Reliant AI is a privately held company founded by former DeepMind and Google Brain researchers Karl Moritz Hermann and Marc Bellemare, alongside life sciences expert Richard Schlegel. The company combines state-of-the-art machine learning techniques with deep biomedical expertise to automate data-intensive workflows across the life sciences, ranging from systematic literature reviews to commercial success prediction. Its platform is designed to enable biopharma teams to make faster, more informed, evidence-based decisions throughout the research and development lifecycle. Dr. Mehmud explained that the proposed platform would integrate Reliant AI’s proprietary generative AI technology with Medicus’ clinical, operational, and internal datasets. The goal is to strengthen data-driven decision-making across Medicus’ clinical pipeline, with a particular focus on improving trial efficiency. Key anticipated capabilities include dynamic clinical-site selection, enhanced patient stratification, and more accurate enrollment forecasting. The initial phase of the collaboration is expected to focus on dynamic site selection supported by targeted patient-stratification analyses for an upcoming Teverelix clinical study, which is planned to begin in 2026. Subject to the execution of definitive agreements, Medicus expects the data analytics platform to be deployed initially in support of a Medicus-sponsored study during the Q2 to Q4 2026 period. There is also potential for the platform to be expanded to support a larger, late-stage clinical study planned for 2028, potentially in collaboration with a development or commercial partner. Medicus Pharma is currently advancing its SKNJCT-003 Phase 2 clinical study, which is being conducted across nine clinical sites in the United States. The study, which began randomizing patients in August 2024, is a randomized, double-blind, placebo-controlled, triple-arm proof-of-concept trial evaluating a non-invasive treatment for basal cell carcinoma of the skin. The study uses Medicus’ novel, patent-protected, dissolvable doxorubicin-containing microneedle array (D-MNA) technology, highlighting the company’s broader commitment to innovation in both therapeutic development and clinical execution. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #GorlinSyndrome #BasalCellCarcinoma #CompassionateUse #FDAApproval #RareDiseaseTreatment #NoninvasiveTherapy #BiotechNews

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce that the company has successfully completed its due diligence process and is preparing to close its acquisition of Krafty Labs on January 2, 2026, subject to customary closing conditions, including approval from the Canadian Securities Exchange (CSE). Gappelberg explained that Krafty Labs brings a highly attractive blue-chip customer roster that includes global technology and enterprise leaders such as Google, Microsoft, Netflix, Oracle, Yelp, ZoomInfo, Spotify, and Meta, among others. In addition to its strong customer base, Krafty Labs has generated approximately $1.2 million in year-to-date 2025 revenue, supported by robust gross margins of roughly 72%, underscoring the scalability and profitability of its platform. Management believes the acquisition will significantly enhance Nextech3D.ai’s AI-first event and engagement ecosystem by adding enterprise-grade capabilities that complement its existing technology stack. The integration of Krafty Labs’ advanced engagement tools with Nextech3D.ai’s in-person, virtual, and hybrid event solutions is expected to expand the company’s reach into higher-value enterprise and association customers. Gappelberg noted that the combined platform is positioned to drive higher average contract values, foster deeper and longer-term customer relationships, and unlock new monetization opportunities across a broad range of event formats. By strengthening its foothold in the enterprise market, Nextech3D.ai aims to accelerate revenue growth while reinforcing its position as a leading provider of AI-powered event and experience technologies. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #ARway #AugmentedReality #SpatialMapping #IndoorNavigation #MapDynamics #EventTech #TradeShowSolutions #TechStocks #ARRevenueGrowth #3DTechnology #ProactiveInvestors #aws #amazonwebservice #tickets #kraftylab

HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) CEO Bo Sears talked with Proactive's Stephen Gunnion about the company’s imminent transition into helium production at its Rudyard project in Montana. Sears confirmed that the PSA compressor, described as the "long lead item," is now en route to site, marking the final step in completing the processing unit. “Once that is delivered and installed, we will be a helium producing company,” Sears told Proactive, emphasizing that all other infrastructure is already in place. The company expects only minor fine-tuning once all components are connected. He noted that despite the upcoming holiday season slowing some activity, HeLIX remains on track. Sears also discussed expanded acreage at Rudyard, which he said has revealed greater potential with each well drilled. HeLIX is waiting for a suitable weather window post-Christmas to continue drilling operations, which were recently delayed by severe weather conditions. On the commercial side, Sears said discussions remain active around helium offtake agreements and potential hydrogen-related partnerships. However, final commitments will only follow first production. “It's just going to take a few days to get this thing plumbed together and in operation mode,” Sears added. “We are really excited about our future here.” Visit Proactive’s YouTube channel for more company interviews and updates. Don’t forget to like this video, subscribe to the channel, and turn on notifications so you don’t miss future content. #HeliumProduction #HeLIXExploration #MontanaEnergy #BoSears #RudyardProject #PSACompressor #EnergyStocks #HydrogenPartnerships #NaturalResources #ProactiveInvestors

Oakmount & Partners Ltd managing director Glenn King talked with Proactive's Stephen Gunnion about the progress investee company Intergroup Mining has made toward its planned listing on the Nasdaq stock exchange. King explained that the submission of legal and accounting documentation to the US Securities and Exchange Commission (SEC) marks a “significant milestone” for Intergroup Mining. “It now means that the company, from a tangible perspective, is just one stage closer to its debut listing,” he said. He noted that while the SEC now enters a review phase, Intergroup can respond to any questions and continue progressing toward its IPO. King also outlined the key compliance steps remaining and highlighted the importance of demonstrating strong financials, clear business plans, and limited share dilution. From an investor perspective, King said a US listing would deliver strategic benefits. “You’re on a notable tier one exchange with deep pools of liquidity,” he noted, adding that it may also position Intergroup as an acquisition target in the coming years. He added that Intergroup Mining produces kaolin, metakaolin, and is also positioned to begin gold production, noting that the project is considered a "legacy mine" with a life expectancy of more than 100 years. Updates are expected around late January or early February, depending on SEC feedback. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #IntergroupMining #NasdaqIPO #OakmountPartners #MiningStocks #Kaolin #GoldMining #Metakaolin #USListing #SECfiling #InvestorUpdates #IPOProcess #CapitalMarkets #ProactiveInvestors

Dekiln CEO Dr Aled Roberts talked with Proactive's Stephen Gunnion about the company’s breakthrough in sustainable ceramic tile production and how £3 million in funding from the Royal Academy of Engineering’s Green Future Fellowship program will help scale the technology. Roberts explained that conventional ceramic tiles have a high carbon footprint due to the energy-intensive kiln-firing process. Dekiln has developed an alternative by mimicking natural processes seen in seashells and tooth enamel, creating tiles that function and feel like ceramics without requiring high-temperature firing. “Our materials are made with very high recycled content,” said Roberts. The tiles are manufactured using recycled gypsum, plastics, and calcium sulfate, combined with a bio-based active ingredient. This not only lowers energy input but significantly reduces carbon emissions in the manufacturing process. The funding will support Dekiln’s transition from lab-scale production—currently at one square metre of tiles per day—to commercial-scale manufacturing. The company has recently moved into a new facility and upgraded to an entry-level commercial press, representing the first step in its scale-up journey. It now aims to work with a UK-based industrial partner to build a pilot plant. For more insights into Dekiln’s progress and the Frontier IP Group, PLC (LSE:FIPP) innovative portfolio, visit Proactive’s YouTube channel, and don’t forget to like this video, subscribe, and enable notifications for updates on future interviews and company developments. #Dekiln #SustainableMaterials #GreenTechnology #NetZero #RoyalAcademyOfEngineering #ClimateTech #RecycledMaterials #CeramicInnovation #LowCarbon #Cleantech

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to provide an update on the company’s strategic initiatives, including progress on its merger with Volato and a new offtake agreement with Next-Gen. Rosende confirmed that the long-anticipated merger with Volato is moving forward after delays caused by a recent government shutdown. “We were able to push it out quickly,” he said, referencing the company’s SEC filing response. The shareholder meeting to approve the merger is scheduled for February 26th, 2026, with the company aiming to close the deal by the end of the first quarter. This milestone is expected to strengthen M2i Global’s software development capabilities, particularly in applications supporting critical mineral supply chains. The CEO also shared details about a new partnership with Next-Gen, which operates a proprietary cathode material process. The facility in Australia will be the first of its kind outside China, and M2i Global has secured an exclusive offtake agreement for the material, expected to begin delivery in approximately two years. Rosende described the development as “really exciting news that we’ll be able to bring that to the United States,” underscoring the strategic importance of securing a stable, non-China-based supply of cathode materials for the North American market. Looking ahead to 2026, Rosende emphasized Volato’s critical role in the company’s broader Critical Minerals Reserve project. Volato will provide software solutions for material tracking, inventory management, and integration with partner operations. A pilot program is planned to validate the technology, ensuring seamless coordination across the supply chain and providing real-time analytics for strategic decision-making. Rosende concluded that these developments position M2i Global to enhance its operational capabilities, secure critical supply sources, and expand its footprint in the rapidly growing market for advanced battery materials and critical minerals. #proactiveinvestors #m2iglobalinc #otcqb #mtwo #CriticalMinerals #SupplyChainSecurity #StrategicMinerals #USDefense #EconomicSecurity #BlockchainLogistics #CriticalMinerals #NevadaMining #parslee #volato #gallium

Replenish Nutrients CEO Neil Wiens joined Steve Darling to outline the company’s transition from development into full commercialization, highlighted by strategic licensing agreements and a significant partnership in the United States. Wiens described 2025 as a pivotal transformation year for Replenish Nutrients. During this period, the company successfully completed its proof-of-concept phase, finalized key intellectual property filings, and moved into commercial-scale operations. “We are physically into that next phase where the licensing deals are real,” Wiens said, emphasizing that the business is now executing on its commercialization strategy rather than preparing for it. A central focus of the discussion was Replenish Nutrients’ recently announced U.S. licensing agreement with Farmers Union Enterprises. The agreement provides the company with access to approximately 70 million acres of farmland, representing a substantial commercial opportunity. Wiens highlighted the favorable timing of the deal, noting its alignment with a newly announced US$700 million USDA regenerative agriculture program. He described the timing as “absolutely fantastic,” as policy support and grower interest in soil health solutions continue to accelerate. Operationally, Wiens confirmed that the company’s Minnesota-based production facility is on track to become operational by June. In parallel, Replenish Nutrients is actively engaged in discussions to expand its footprint into four additional U.S. states. Beyond North America, the company is also evaluating opportunities in Brazil, citing strong synergies in nutrient usage and alignment with its existing supply chain partner. Wiens reiterated that farmer return on investment remains the cornerstone of adoption. “If I can get soil health plus keep my yield the same or better and also start decreasing my fungicide and pesticide use – I win as a farmer,” he said, underscoring the value proposition Replenish aims to deliver to growers. Looking ahead to 2026, Replenish Nutrients plans to scale its global presence while maintaining its operational and corporate base in Canada, positioning the company to benefit from the growing global focus on regenerative agriculture and sustainable food production. #proactiveinvestors #replenishnutrientsholdingscorp #cse #erth #otc #vvivf #RegenerativeAgriculture #FertilizerInnovation #SustainableFarming #CropGrowth #NeilWiens #AgricultureNews #Farming2025 #ProactiveInvestors #SustainableSolutions #Agritech #FertilizerInnovation #MJAgSolutions #PelletFertilizer #ProbioticSoil #BeisekerFacility #CanadianAgriculture

ProPhase Labs CEO Ted Karkus joined Steve Darling from Proactive to announce that the company has entered into a non-binding Letter of Intent (LOI) regarding a proposed reverse merger transaction with Advanced Biological Laboratories (ABL), a European biotechnology and MedTech group. Under the proposed structure, Advanced Biological would become the majority owner of the combined public entity, while ProPhase’s existing operations would continue as sister companies to a newly formed U.S. subsidiary expected to remain under ProPhase’s current management team. Karkus emphasized that the transaction remains subject to the execution of definitive agreements, regulatory approvals, and board authorization. However, the parties have discussed a preliminary, non-binding valuation framework that could imply an enterprise value of up to approximately US$30 million for ProPhase’s legacy business. This framework is intended to provide a basis for ongoing negotiations rather than a final valuation. As outlined in the LOI, and subject to applicable law and final documentation, ProPhase Labs may declare a special cash dividend of up to US$10 million payable to shareholders of record on a date to be determined. Importantly, any such dividend would be distributed separately and would not be part of the merged operating company. In addition, all Crown Medical Collections receivables are expected to be carved out and retained exclusively for the benefit of current ProPhase shareholders, further preserving value for existing investors. Advanced Biological Laboratories would contribute its global biotechnology and MedTech infrastructure to the combined company, including advanced health data processing platforms, cloud-based computing capabilities, and access to international financing resources. The combination is intended to create a more diversified healthcare technology platform with expanded global reach, while allowing ProPhase to unlock value for shareholders through potential cash distributions and retained assets. #proactiveinvestors #prophaselabs #nasdaq #prph #biotech #genomics #genomesequencing #ProPhaseLabs #AdvancedBiologicalLaboratories #ReverseMerger #LOI #Biotechnology #MedTech #HealthcareTechnology #StrategicTransaction #ShareholderValue #SpecialDividend #NasdaqListed #GlobalHealthcare #HealthData #CloudComputing #LifeSciences #MergersAndAcquisitions

Cabbacis CEO Joe Pandolfino joined Steve Darling from to discuss the company’s strategic preparations to enter the U.S. market with its proprietary low-nicotine tobacco products. Cabbacis is a federally licensed tobacco product manufacturer with a robust intellectual property portfolio that includes 35 issued patents worldwide, covering its iBlend™ cigarettes and vaporizer pod technology. The company operates out of a manufacturing facility in Niagara Falls, New York, and is led by a management team that brings more than 50 years of combined experience in the tobacco industry. Pandolfino explained that iBlend™ products have been specifically engineered to align with anticipated regulatory changes in the United States. He noted that the U.S. Food and Drug Administration is advancing a rule that could require a reduction of nicotine levels in all cigarettes sold in the country by approximately 95%. “The FDA is moving forward a rule which would mandate the reduction of nicotine in all cigarettes sold in the United States by about 95%,” Pandolfino said, positioning iBlend™ as a potential solution for a post-regulation tobacco market. Cabbacis’ strategy centers on improving consumer acceptance of very low nicotine cigarettes, which multiple peer-reviewed studies have shown can significantly reduce smoking frequency and nicotine dependence. Pandolfino highlighted that the company’s proprietary blend incorporates hemp alongside tobacco, a formulation that internal focus group research indicates is more appealing to smokers than traditional very low nicotine products. Looking ahead, Cabbacis plans to conduct additional studies in the first quarter of 2026 to support regulatory submissions. The company is targeting the submission of a Pre-Market Tobacco Application (PMTA) to the FDA for its iBlend™ products in the first half of 2026. Pandolfino told Proactive that achieving FDA authorization would mark a major milestone and could position Cabbacis as an early mover in a rapidly evolving, regulation-driven U.S. tobacco landscape. #proactiveinvestors #cabaccis #otcqb #cabi #Cabbacis #iBlend #LowNicotine #TobaccoInnovation #FDARegulation #PMTA #NicotineReduction #HarmReduction #TobaccoIndustry #SmokingCessation #RegulatoryStrategy #IntellectualProperty #PatentedTechnology #USMarketEntry #ConsumerHealth